African Traditional Herbal Research Clinic ... - Blackherbals.com
African Traditional Herbal Research Clinic ... - Blackherbals.com African Traditional Herbal Research Clinic ... - Blackherbals.com
Four New Malaria DrugsInventedDaily MonitorMay 7, 2007Jane NafulaAfter a seven-year search for the best drug that can curemalaria, the Medicines for Malaria Venture, (MMV), anon-profit making organisation has finally developed fournew highly effective anti-malarial drugs.The NGO with headquarters in Geneva, Switzerland isdedicated to reducing the burden of malaria in diseaseendemiccountries by discovering, developing anddelivering new affordable anti-malarials through effectivepublic-private partnerships.MMV’s Vice President Public Affairs Anna Wang toldjournalists in Kampala on Saturday that the four drugs arein the pipeline and would be ready within the next twoyears.“Clinical trials started three years ago and we are now inthe last stage of developing the new and affordable drugsto ensure universal access. Almost half of people whosuffer from malaria don’t have access to drugs becausethey are expensive,” Ms Wang said.She said by mid next year, one of the drugs, pediatriccoartem, a formulation for children would be ready.Children under five years and women are vulnerable tomalaria because of their low immunity levels.Ms. Wang said the other three drugs are ArteminisinbasedCombination Therapy with different formulationswhich include, Pyramax, DHA-PIQ (Dihydroartemisinin/Piper-aquine), and LapDap combined with artesunate(CDA).The NGO will today hold a stakeholders’ meeting atSpeke Resort Munyonyo. President Yoweri Museveni isexpected to officiate at the opening of the meeting.According to Ms Wang, a patient is supposed to swallowone table for three days and afterwards he or she will berelieved of the disease.The drugs will be supplied in endemic countriesincluding Uganda. This will be done in collaboration withthe Ministries of Health, researchers and otherstakeholders both in private and public sectors.MMV’s goal will register at least four new anti-malarialsbefore 2010 and maintain a sustainable pipeline of antimalarialsto meet the needs of over 3.2 billion people atrisk from this deadly disease.-10- Traditional African Clinic July/August 2007Last year alone, the organization injected about $50 millionin the development of the drugs. Donors mainly fund itsactivities. The new treatment could be an importantdevelopment in the fight against malaria, which isescalating mainly due to multi-drug resistance including themost frequently use and affordable treatments for malaria,such chloroquine.The available Artemisinin-based Combination Therapy(ACTs) are relatively expensive, currently costingapproximately US$1.20-3.50 (SHS 8,000) per adult dose.Globally, malaria kills between one and two million peopleannually.According to Unicef, malaria infects 350 to 500 millionpeople each year, kills a child somewhere in the worldevery 30 seconds, accounts for about one in five of allchildhood deaths, and is most prevalent in Africa.☻☻☻☻☻☻Study Suggests New MalariaDrugDaily MonitorMay 28, 2007Kakaire A. KirundaA new study suggests there is a better alternative to thecurrent first-line drugs for the treatment of uncomplicatedmalaria in the country.The study suggests the DP (dihydroartemisinin-piperaquinedrug combination appears to be a good alternative to AL(artemether-lumefantrine) as first-line treatment ofuncomplicated malaria. DP is popularly known by thebrand name Duo Cotecxin while AL is what is branded asCoartem.The study was carried out in Apac, a district with highmalaria transmission intensity. Its findings were publishedin the PLoS Clinical Trials Journal of May 18. Researchersfrom Makerere University Medical School and the Instituteof Public Health as well as their counterparts from the UK,USA and Thailand carried out the study.“Patients treated with DP had a lower risk of recurrentparasitemia due to non-falciparum species, development ofgametocytemia, and higher mean increase in haemoglobincompared to patients treated with AL,” says the study.“Both drugs were well tolerated; serious adverse eventswere uncommon and unrelated to study drugs.”Continued on age 11
Continued from page 7 – President Bush donates 500,000Mosquito Nets“We are committed to helping our African partners buildon these efforts, and so I want to share with you two newendeavours: First, America will expand our cooperationwith the government of Uganda, and the non-profitgroup, Malaria No More, to distribute more than a half-amillionbed nets in Uganda,” President Bush said.Malaria is one of the most deadly and prevalent diseasesin Sub-Saharan Africa and also the most preventable andtreatable. More than 1 million people die of malaria eachyear, 75 percent of them African children, and more than300 million people worldwide fall ill from malariaannually.According to the 2006 Malaria Country Action Plan forUganda, household ownership of bed nets is only 25%and that only 15% of children under five are sleepingunder a treated bed net. The President’s Malaria Initiativeestablished a goal that 85% of children under five and85% of all pregnant women will have slept under a bednet by 2010.“Working in partnership with the President’s MalariaInitiative and Malaria No More will produce a total of530,000 bed nets for Uganda together,” according to theorganisation’s website.☻☻☻☻☻☻Ministry, PMI in JointCampaign against MalariaIsaiah Kitimbo, KaliroDaily MonitorApril 30, 2007The President’s Malaria Initiative, Malaria No More, andthe Ministry of Health have started a joint campaign todistribute 580,000 insecticide-treated mosquito nets.The nets are to be distributed to pregnant women,children under five and other vulnerable people in 26districts.The group last week launched the free mosquito netdistribution campaign at Kaliro district headquarters.The ceremony was officiated by the Health MinisterStephen Mallinga.Malaria is the leading cause of death in Uganda.Paid for by PMI and Malaria No More, the nets will bedistributed alongside 1.8 million others from the GlobalFund.“This is an example of how collaboration can help us withour mission: saving lives together and working togethertowards our common goal of stopping malaria” PMICoordinator Tim Ziemer said in a press release.“It will only be through working hand in hand with otherorganizations that we achieve our goal given to us byPresident Bush of stopping malaria and protecting thosewho are most susceptible and in most need.”President Bush launched the PMI in 2005 and challenge therest of the world to match the $1.2 billion pledge, to reducemalaria deaths by 50 per cent in 15 African countries.Mr. Bush urged that the PMI be a collaborative USgovernment effort led by the US Agency for InternationalDevelopment (USAID).☻☻☻☻☻☻Continued from page 10 – Study Suggests New Malaria DrugAccording to the researchers, Duo Cotecxin was superior toCoartem for reducing the risk of recurrent parasitemia andgametocytemia, and provided improved hemoglobinrecovery.Parasitemia is the quantitative content of parasites in theblood while gametocytes refer to one of the stages in thelife cycle of the malaria parasite. Gametocytemia thereforemeans the parasites presence in the blood.The study findings show that patients treated with DuoCotecxin had a significantly lower risk of recurrentparasitemia in both falciparum and non-falciparuminfections.Both Duo Cotecxin and Coartem are fixed dose coformulatedArtemisinin-based combination therapies(ACTs). ACTs are a newer group of anti-malarials thatproduce fast response in patients, are active against multidrug-resistantP. falciparum malaria, are well tolerated bypatients and have the potential to reduce malariatransmission by decreasing gametocyte carriage.However, researchers contend that Duo Cotecxin has asimpler, once daily dosing schedule compared to Coartem,which is provided twice daily, ideally with a fatty meal.Despite the excellent initial parasite clearance by thetwo drugs as indicated in the study and the provision ofinsecticide treated nets at enrollment, the researchersobserved that approximately half of all participantsexperienced recurrent malaria within 42 days.The researchers said the finding emphasizes the need formore aggressive approaches to malaria control in areas withvery high malaria transmission.-11- Traditional African Clinic July/August 2007To reduce new malaria infections, they called a sustainedContinued on page 12
- Page 2 and 3: Continued from page 1 - Malaria Rat
- Page 4 and 5: African Traditional Herbal Research
- Page 6: African Traditional Herbal Research
- Page 9: Continued from page 8 - How Malaria
- Page 13 and 14: Continued from page 12 -Shs3.7b Mal
- Page 15 and 16: Continued from page 14 - Does it Ma
- Page 17 and 18: Continued from page 16 - No Money f
- Page 19 and 20: African Traditional Herbal Research
- Page 21 and 22: Continued from page 20 - DDT will n
- Page 23 and 24: Cheap anti-Malaria DrugComing to Af
- Page 25 and 26: Continued from page 24 - ICRAF disc
- Page 27 and 28: Continued from page 26 - Case Study
- Page 29 and 30: Continued from page 28 - Scientists
Four New Malaria DrugsInventedDaily MonitorMay 7, 2007Jane NafulaAfter a seven-year search for the best drug that can curemalaria, the Medicines for Malaria Venture, (MMV), anon-profit making organisation has finally developed fournew highly effective anti-malarial drugs.The NGO with headquarters in Geneva, Switzerland isdedicated to reducing the burden of malaria in diseaseendemiccountries by discovering, developing anddelivering new affordable anti-malarials through effectivepublic-private partnerships.MMV’s Vice President Public Affairs Anna Wang toldjournalists in Kampala on Saturday that the four drugs arein the pipeline and would be ready within the next twoyears.“<strong>Clinic</strong>al trials started three years ago and we are now inthe last stage of developing the new and affordable drugsto ensure universal access. Almost half of people whosuffer from malaria don’t have access to drugs becausethey are expensive,” Ms Wang said.She said by mid next year, one of the drugs, pediatriccoartem, a formulation for children would be ready.Children under five years and women are vulnerable tomalaria because of their low immunity levels.Ms. Wang said the other three drugs are ArteminisinbasedCombination Therapy with different formulationswhich include, Pyramax, DHA-PIQ (Dihydroartemisinin/Piper-aquine), and LapDap <strong>com</strong>bined with artesunate(CDA).The NGO will today hold a stakeholders’ meeting atSpeke Resort Munyonyo. President Yoweri Museveni isexpected to officiate at the opening of the meeting.According to Ms Wang, a patient is supposed to swallowone table for three days and afterwards he or she will berelieved of the disease.The drugs will be supplied in endemic countriesincluding Uganda. This will be done in collaboration withthe Ministries of Health, researchers and otherstakeholders both in private and public sectors.MMV’s goal will register at least four new anti-malarialsbefore 2010 and maintain a sustainable pipeline of antimalarialsto meet the needs of over 3.2 billion people atrisk from this deadly disease.-10- <strong>Traditional</strong> <strong>African</strong> <strong>Clinic</strong> July/August 2007Last year alone, the organization injected about $50 millionin the development of the drugs. Donors mainly fund itsactivities. The new treatment could be an importantdevelopment in the fight against malaria, which isescalating mainly due to multi-drug resistance including themost frequently use and affordable treatments for malaria,such chloroquine.The available Artemisinin-based Combination Therapy(ACTs) are relatively expensive, currently costingapproximately US$1.20-3.50 (SHS 8,000) per adult dose.Globally, malaria kills between one and two million peopleannually.According to Unicef, malaria infects 350 to 500 millionpeople each year, kills a child somewhere in the worldevery 30 seconds, accounts for about one in five of allchildhood deaths, and is most prevalent in Africa.☻☻☻☻☻☻Study Suggests New MalariaDrugDaily MonitorMay 28, 2007Kakaire A. KirundaA new study suggests there is a better alternative to thecurrent first-line drugs for the treatment of un<strong>com</strong>plicatedmalaria in the country.The study suggests the DP (dihydroartemisinin-piperaquinedrug <strong>com</strong>bination appears to be a good alternative to AL(artemether-lumefantrine) as first-line treatment ofun<strong>com</strong>plicated malaria. DP is popularly known by thebrand name Duo Cotecxin while AL is what is branded asCoartem.The study was carried out in Apac, a district with highmalaria transmission intensity. Its findings were publishedin the PLoS <strong>Clinic</strong>al Trials Journal of May 18. <strong>Research</strong>ersfrom Makerere University Medical School and the Instituteof Public Health as well as their counterparts from the UK,USA and Thailand carried out the study.“Patients treated with DP had a lower risk of recurrentparasitemia due to non-falciparum species, development ofgametocytemia, and higher mean increase in haemoglobin<strong>com</strong>pared to patients treated with AL,” says the study.“Both drugs were well tolerated; serious adverse eventswere un<strong>com</strong>mon and unrelated to study drugs.”Continued on age 11
Change language